Edwin Posadas, MD

Director,Cancer Therapeutics Program; Medical Director, Center for Uro-Oncology Research Excellence (CURE) - Cedars-Sinai-Cancer

[Ravi A Madan M.D. @Dr_RaviMadan]

Appreciate the⚠️caution voiced by #PCWG4 @AarmstrongDuke et al.@JCO_ASCO

#PSMA imaging in #ProstateCancer is not🚫ready for prime time to determine treatment failure (distinct from imaging PD) in clinical practice

PSMA may harm pts if it leads to stopping a tx too quickly

[Jun Gong, MD @jgong15]

Great way to cap off #colorectalcancer awareness month hosting our @CSCancerCenter #CRC research social w/Dr. Alessio Pigazzi @EdwinPosadasMD for a productive exchange of ideas, networking & future collabs w/PhDs & MDs in #CRC research @AGangiMD @fdossa @SGrivennikov @SekiEki

[Ravi A Madan M.D. @Dr_RaviMadan]

The @thenci past meets the present @asco #GU26

Dr. Melissa Abel @melissaabel20 discusses emerging #PSMA tumor volume data with Dr. Harpreet Singh @harpreet_md

The emerging data is from a follow-up trial based on a trial Dr. Singh worked on during her time @theNCI

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Breaking news from @ASCO #GU26 👉Adding belzutifan to adjuvant pembrolizumab significantly improves disease free survival (HR: 0.72)👉Congrats @drchoueiri & team for changing SOC again in pts with #kidneycancer @kidneycan @OncoAlert @urotoday

[Edwin Posadas, MD @EdwinPosadasMD]

Dual masking T-cell engagers do sounds VERY interesting #GU26.

[Edwin Posadas, MD @EdwinPosadasMD]

Dr Joshua Watson showing novel biology associated with #livermetastases in #prostatecancer! Proud of his exciting work #GU26

[Ravi A Madan M.D. @Dr_RaviMadan]

As we get ready for the update on the overall survival in #BRCAAway trial @asco #GU26

It is worth noting the small number of patients that’s crossed over.

In that context this data has its limits in comparing combination vs sequence in #ProstateCancer

[Edwin Posadas, MD @EdwinPosadasMD]

Great points from Dr. Koontz. Biology should drive decision making #GU26

[Jun Gong, MD @jgong15]

@AmarUKishan POSEIDON meta-analysis of 6 PhIII RCTs on hormonal therapy (HT) after post-op RT (PORT) in localized #Prostatecancer ➡️ no OS benefit w/HT to PORT & no significant interaction b/t duration of HT & this effect (p-interaction 0.25) for PSA<0.5

#GU26 @OncoAlert

[Ravi A Madan M.D. @Dr_RaviMadan]

#BRCAaway OS data presented by Dr. Maha Hussein

#GU26 @asco

Launched prior to large phase 3s in #ProstateCancer Cancer

Provocative data but as Dr Hussein acknowledges small numbers in cross over (8 patients) limits ability to truly understand sequencing vs combo

[Ravi A Madan M.D. @Dr_RaviMadan]

Dr Evan Yu takes stage @asco #GU26 to discuss #Peace3 & #BRCAaway

Too often superlatives are thrown around on this app…

But do yourself a favor. Watch this whole discussion. One of the more thoughtful takes on modern clinical trial dilemmas in #ProstateCancer

Thank you Dr Yu

[Edwin Posadas, MD @EdwinPosadasMD]

@katy_beckermann @TNOncology Not sure if you can draw that conclusion given the limited Cross over. Dr Yu’s comment about better studies rings true

[Ravi A Madan M.D. @Dr_RaviMadan]

It’s always a beautiful day when you can go to clinic and observe a successful #bicalutamide withdrawal maneuver
📉

Yes… even in 2025 🙂

Sometimes less is more in #ProstateCancer (#nmCRPC)

Flashback to Dr. Evan Yu & colleagues…
https://t.co/DjuJ6NfR9h

[Edwin Posadas, MD @EdwinPosadasMD]

@angela_jia_ great job at the podium today at #ASCO25 You have become a pro!

[Edwin Posadas, MD @EdwinPosadasMD]

What did I learn at #ASCO2025 ?
1. Increasing intensity of treatment improves PFS& toxicity- still need OS data for shared decision making
2. Powerful new treatments for #ProstateCancer are coming. get patients on trial
3. Get biomarkers on your #ProstateCancer
Thanks everyone!

[Ravi A Madan M.D. @Dr_RaviMadan]

As new #mCSPC #PFS data is unveiled w/#PARP & Lu-PSMA it is worth nothing all previous mCSPC trials showed OS despite large functional cross overs

Did we lower standard to PFS when both agents are approved for mCRPC?
🤔

#ProstateCancer #ASCO25
https://t.co/QOdBqMuBYC

[Daniel E Spratt @DrSpratticus]

Another proud @RadOncUH Chair moment to see our soon to be newest faculty @Soum_Roy_RadOnc being recognized for his statistical brilliance in collaboration with #IRONMAN #ASCO25 @ASCO

Way to go!

@JasonBrownMDPhD @PBarataMD @jeshoag @LPonsky @GUONCGarciaJA @TedTeknosMD @DanSimonMD

[Edwin Posadas, MD @EdwinPosadasMD]

Amazing what STAMPEDE has done for science: the US needs to do something this important for prostate cancer #ASCO25

[Edwin Posadas, MD @EdwinPosadasMD]

nice job by @MichaelOng_MD promoting the need to support TRIPLE-SWTICH… let’s see if acting on this PSA threshold is important. #ASCO25

[Mary Feng @MaryFengMD]

Thanks for welcoming the second generation Feng to ASCO! What’s your #ASCO25 happy dance? @DrChoueiri @nlinmd @DrKarenKnudsen @DrPaulNguyen @APDicker @EdwinPosadasMD @DrKatePedersen @JoshLangMD @PamelaKunzMD @fumikochino